Fermer le menu


Member of Lyonbiopole


GlycoBAR is a biotech which owns a biofermentation technology allowing to produce blood group antigen ligands at a cost that is - for the first time ever - compatible with the market. Thanks to these molecules, It becomes possible to make "universal plasma" or "universal platelets", meaning not grouped any more, compatible with any recipient whichever is the group of the donor. The same molecule allows organ transplants between donor and recipient of a different blood group. Last: now plasma derivative drug (IgM based) are becoming a reality.


Application market: Public Health & Patient care, Others

Type of activity: Technology provider, Therapeutics, Pharma or Biotech

Technologies: Others

Created on sept. 15th, 2015 - 4 employees



Espace Colombiers - 19 rue Casimir Julhiet 38420 Domène



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.